Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update
March 22, 2023 16:05 ET | Rani Therapeutics, LLC
- Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of osteoporosis - -...
Adalimumab Global Market Report 2022: Rising Prevalence of Arthritis and Clinical Trials to Spur Growth
February 22, 2023 09:33 ET | Research and Markets
Dublin, Feb. 22, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028: Segmented By Type (Biologics v/s Biosimilars), By...
Chinese Anti-Rheumatic Drug Market
China Anti-Rheumatic Drug Market Forecasts Report 2022-2027 - Growing Prevalence of Rheumatic Patients Leading to Increased Demand
January 20, 2023 06:58 ET | Research and Markets
Dublin, Jan. 20, 2023 (GLOBE NEWSWIRE) -- The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.China Antirheumatic Drugs...
Global Adalimumab, Infliximab And Etanercept Biosimilars Market
Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023: Increasing Healthcare Access Bolsters Sector
January 11, 2023 04:48 ET | Research and Markets
Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ...
Samsung Bioepis Presents Three-year Follow-up Data of Adalimumab Biosimilar SB5 in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
September 07, 2022 02:01 ET | Samsung Bioepis
Long term follow-up data from British Association of Dermatologics and Immunomodulators Register (BADBIR) shows safety and effectiveness of SB5 in patients with psoriasis who have started or...
Samsung Bioepis Announces New Data on Adalimumab Biosimilar, SB5 at the Annual European Congress of Rheumatology (EULAR 2022)
May 31, 2022 18:05 ET | Samsung Bioepis
Samsung Bioepis and Biogen to present one abstract and one poster at EULAR 2022 on adalimumab biosimilar, SB5 including Phase 1 study of a new SB5 formulation and a pan-European real-world study,...
Coherus BioSciences, Inc. logo
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
March 29, 2022 09:15 ET | Coherus BioSciences, Inc.
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2...
Coherus BioSciences, Inc. logo
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
March 15, 2022 08:00 ET | Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Rosh Dias, MD, MRCP, has been appointed Chief Medical...
Coherus BioSciences, Inc. logo
Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh)
December 20, 2021 07:59 ET | Coherus BioSciences, Inc.
- Approved for all eligible indications of the reference biological product, Humira® (adalimumab) - - YUSIMRY is Coherus' second FDA-approved product - REDWOOD CITY, Calif., Dec. 20, 2021 (GLOBE...
HUMIRA (Adalimumab) Biosimilars Market Report 2021: Current Developer Landscape and Clinical Research Scenario Related to All the Follow-on Products of the Blockbuster Biologic Drug
July 30, 2021 06:03 ET | Research and Markets
Dublin, July 30, 2021 (GLOBE NEWSWIRE) -- The "HUMIRA? (Adalimumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars,...